MORE ON THE US AGENCY FOR HEALTHCARE RESEARCH AND QUALITY REPORT ON MS DRUGS, via C.C.S.V.I. Ontario

MS neuros and pharma don't like this at all

"The review concluded that meager information exists to guide patients and their physicians in making decisions about discontinuing DMTs. The authors stated that there's little evidence suggesting long-term harms are any greater than short-term harms for patients taking DMTs. Similarly, they stated that there's little evidence supporting long-term benefits from DMTs for patients with relapsing-remitting MS (RRMS)."


MS Community Flares Over AHRQ Report
www.medpagetoday.com
Controversy erupts over review of MS drug discontinuation strategies.